News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
News Pfizer takes 25-valent Prevnar follow-up into phase 3 Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.
News Doctors dismayed by report of NHS AI proposal The British Medical Association has branded a leaked proposal to rein back NHS recruitment and use more AI to compensate a "massive gamble."
News As Ebola deaths climb, search begins for vaccine The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.
News GHO, CBC merge to create largest healthcare investment firm Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.
News Tuneable peptide biotech Parabilis files IPO Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.